• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组蛋白去乙酰化酶2通过上调纤连蛋白促进非小细胞肺癌细胞的迁移和侵袭。

HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.

作者信息

Li Li, Mei Dr Tonghua, Zeng Yun

机构信息

Department of Respiratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, PR China.

Department of Respiratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, PR China.

出版信息

Biomed Pharmacother. 2016 Dec;84:284-290. doi: 10.1016/j.biopha.2016.09.030. Epub 2016 Sep 22.

DOI:10.1016/j.biopha.2016.09.030
PMID:27665474
Abstract

Recent studies indicated that histone deacetylases (HDACs) can modulate the tumorigenesis and development of cancer cells. We evaluated the expression of class I HDACs in non-small cell lung cancer (NSCLC) cells and found that HDAC2 was significantly increased in NSCLC cells as compared with the normal bronchial epithelial cell line BEAS-2B. Silencing of HDAC2 by its specific siRNAs can significantly inhibit the in vitro migration and invasion of A549 and H1395 cells. While over expression of HDAC2 by transfection of pcDNA/HDAC2 plasmid can trigger the motility of NSCLC cells. Over expression of HDAC2 increased the protein and mRNA expression of firbronectin (FN), which can accelerate the metastasis of cancer cells. Similarly, knock down of HDAC2 suppressed the expression of FN. The inhibitor of NF-κB, while not ERK1/2 or PI3K/Akt, attenuated HDAC2 induced up regulation of FN and invasion of NSCLC cells. Furthermore, HDAC2 can markedly increase both mRNA and protein levels of p65 in NSCLC cells. Collectively, our data revealed that HDAC2 can trigger migration and invasion of NSCLC cells via up regulation FN through activation of NF-κB. It suggested HDAC2 might be a potential therapeutic target for the drug development of NSCLC patients.

摘要

近期研究表明,组蛋白去乙酰化酶(HDACs)可调控癌细胞的肿瘤发生与发展。我们评估了I类HDACs在非小细胞肺癌(NSCLC)细胞中的表达,发现与正常支气管上皮细胞系BEAS-2B相比,NSCLC细胞中HDAC2显著增加。通过其特异性小干扰RNA(siRNAs)沉默HDAC2可显著抑制A549和H1395细胞的体外迁移和侵袭。而转染pcDNA/HDAC2质粒过表达HDAC2可引发NSCLC细胞的运动性。HDAC2过表达增加了纤连蛋白(FN)的蛋白质和mRNA表达,这可加速癌细胞的转移。同样,敲低HDAC2可抑制FN的表达。NF-κB抑制剂而非ERK1/2或PI3K/Akt抑制剂可减弱HDAC2诱导的FN上调和NSCLC细胞的侵袭。此外,HDAC2可显著增加NSCLC细胞中p65的mRNA和蛋白质水平。总体而言,我们的数据表明HDAC2可通过激活NF-κB上调FN来触发NSCLC细胞的迁移和侵袭。这表明HDAC2可能是NSCLC患者药物开发的潜在治疗靶点。

相似文献

1
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.组蛋白去乙酰化酶2通过上调纤连蛋白促进非小细胞肺癌细胞的迁移和侵袭。
Biomed Pharmacother. 2016 Dec;84:284-290. doi: 10.1016/j.biopha.2016.09.030. Epub 2016 Sep 22.
2
Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).M2型乙酰胆碱受体/核因子κB信号轴失活可逆转非小细胞肺癌(NSCLC)中的上皮-间质转化(EMT),并抑制其迁移和侵袭。
Oncotarget. 2015 Oct 6;6(30):29335-46. doi: 10.18632/oncotarget.5004.
3
Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.剪接因子 4 靶向 NF-κB/环氧化酶-2 信号通路促进肺癌生长和进展。
Cancer Lett. 2016 Oct 10;381(1):1-13. doi: 10.1016/j.canlet.2016.07.016. Epub 2016 Jul 20.
4
Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.核内组蛋白去乙酰化酶6通过抑制核因子κB/基质金属蛋白酶2来抑制侵袭,且与非小细胞肺癌转移呈负相关。
Oncotarget. 2015 Oct 6;6(30):30263-76. doi: 10.18632/oncotarget.4749.
5
Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung cancer.在人类非小细胞肺癌中,原癌基因LSD1通过miR-137的过表达在表观遗传上受到抑制。
Biochimie. 2017 Jun;137:12-19. doi: 10.1016/j.biochi.2017.02.010. Epub 2017 Feb 20.
6
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.内脂素通过上调基质金属蛋白酶触发非小细胞肺癌的细胞运动。
Basic Clin Pharmacol Toxicol. 2016 Dec;119(6):548-554. doi: 10.1111/bcpt.12623. Epub 2016 Jul 21.
7
Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.白藜芦醇通过下调人非小细胞肺癌细胞中ERK1/2和AKT介导的X射线修复交叉互补组1(XRCC1)蛋白表达增强依托泊苷诱导的细胞毒性。
Basic Clin Pharmacol Toxicol. 2015 Dec;117(6):383-91. doi: 10.1111/bcpt.12425. Epub 2015 Jun 30.
8
Src Promotes Metastasis of Human Non-Small Cell Lung Cancer Cells through Fn14-Mediated NF-κB Signaling.Src 通过 Fn14 介导的 NF-κB 信号促进人非小细胞肺癌细胞的转移。
Med Sci Monit. 2018 Mar 3;24:1282-1294. doi: 10.12659/msm.906266.
9
Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.长链非编码RNA PVT1表达增加促进非小细胞肺癌的肿瘤发生。
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6929-35. eCollection 2014.
10
Grb2-associated binder 2 silencing impairs growth and migration of H1975 cells via modulation of PI3K-Akt signaling.Grb2相关结合蛋白2沉默通过调节PI3K-Akt信号传导损害H1975细胞的生长和迁移。
Int J Clin Exp Pathol. 2015 Sep 1;8(9):10575-84. eCollection 2015.

引用本文的文献

1
miR-490-5p inhibits the progression of osteosarcoma by targeting HDAC2.微小RNA-490-5p通过靶向组蛋白去乙酰化酶2抑制骨肉瘤进展。
Transl Cancer Res. 2025 Jul 30;14(7):4357-4368. doi: 10.21037/tcr-2024-2217. Epub 2025 Jul 22.
2
Deciphering the Mysterious Relationship between the Cross-Pathogenetic Mechanisms of Neurodegenerative and Oncological Diseases.解析神经退行性和肿瘤性疾病的交叉发病机制之谜。
Int J Mol Sci. 2023 Sep 29;24(19):14766. doi: 10.3390/ijms241914766.
3
HDAC2 as a target for developing anti-cancer drugs.组蛋白去乙酰化酶2作为开发抗癌药物的靶点。
Comput Struct Biotechnol J. 2023 Mar 13;21:2048-2057. doi: 10.1016/j.csbj.2023.03.016. eCollection 2023.
4
HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism.组蛋白去乙酰化酶抑制剂 ITF2357 通过 HDAC2/miR-130a-3p 依赖的机制降低了突变型-KRAS 非小细胞肺癌对培美曲塞的耐药性。
J Transl Med. 2023 Feb 15;21(1):125. doi: 10.1186/s12967-023-03973-3.
5
Signatures of Co-Deregulated Genes and Their Transcriptional Regulators in Lung Cancer.肺癌中共同失调基因及其转录调控因子的特征。
Int J Mol Sci. 2022 Sep 18;23(18):10933. doi: 10.3390/ijms231810933.
6
High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors.非功能性垂体瘤中组蛋白去乙酰化酶2/3的高表达
Front Oncol. 2022 May 13;12:875122. doi: 10.3389/fonc.2022.875122. eCollection 2022.
7
A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.一类新型的抗癌双重 HDAC2/FAK 抑制剂,含有被吡啶基-1,2,4-三唑封端的羟肟酸/苯甲酰胺。
Eur J Med Chem. 2021 Oct 15;222:113569. doi: 10.1016/j.ejmech.2021.113569. Epub 2021 May 29.
8
Targeting Histone Modifications in Bone and Lung Metastatic Cancers.靶向骨和肺转移癌中的组蛋白修饰。
Curr Osteoporos Rep. 2021 Jun;19(3):230-246. doi: 10.1007/s11914-021-00670-2. Epub 2021 Mar 15.
9
Histone deacetylase inhibitors differentially regulate c-Myc expression in retinoblastoma cells.组蛋白去乙酰化酶抑制剂对视网膜母细胞瘤细胞中c-Myc的表达有不同的调节作用。
Oncol Lett. 2020 Jan;19(1):460-468. doi: 10.3892/ol.2019.11111. Epub 2019 Nov 19.
10
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.NOS1 通过 HDAC2 的 S-亚硝基化抑制癌细胞的干扰素反应。
J Exp Clin Cancer Res. 2019 Dec 5;38(1):483. doi: 10.1186/s13046-019-1448-9.